JP2004502682A - 銅含有アミン・オキシダーゼの阻害剤 - Google Patents

銅含有アミン・オキシダーゼの阻害剤 Download PDF

Info

Publication number
JP2004502682A
JP2004502682A JP2002507795A JP2002507795A JP2004502682A JP 2004502682 A JP2004502682 A JP 2004502682A JP 2002507795 A JP2002507795 A JP 2002507795A JP 2002507795 A JP2002507795 A JP 2002507795A JP 2004502682 A JP2004502682 A JP 2004502682A
Authority
JP
Japan
Prior art keywords
alkyl
substituted
heterocyclic ring
hydrogen
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002507795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004502682A5 (enExample
Inventor
スミス，デイビッド　ジョン
ヤルカネン，マルック
フュレプ，フェレンツ
ラーザール，ラースロー
サコニュイ，ゾルト
ベルナーツ，ガーボル
Original Assignee
バイオティ　セラピーズ　コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオティ　セラピーズ　コーポレイション filed Critical バイオティ　セラピーズ　コーポレイション
Publication of JP2004502682A publication Critical patent/JP2004502682A/ja
Publication of JP2004502682A5 publication Critical patent/JP2004502682A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2002507795A 2000-07-05 2001-07-04 銅含有アミン・オキシダーゼの阻害剤 Withdrawn JP2004502682A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21634100P 2000-07-05 2000-07-05
PCT/FI2001/000637 WO2002002541A2 (en) 2000-07-05 2001-07-04 Inhibitors of copper-containing amine oxidases

Publications (2)

Publication Number Publication Date
JP2004502682A true JP2004502682A (ja) 2004-01-29
JP2004502682A5 JP2004502682A5 (enExample) 2005-03-03

Family

ID=22806663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002507795A Withdrawn JP2004502682A (ja) 2000-07-05 2001-07-04 銅含有アミン・オキシダーゼの阻害剤
JP2002506712A Withdrawn JP2004501962A (ja) 2000-07-05 2001-07-04 銅含有アミン・オキシダーゼの阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2002506712A Withdrawn JP2004501962A (ja) 2000-07-05 2001-07-04 銅含有アミン・オキシダーゼの阻害剤

Country Status (14)

Country Link
US (2) US6624202B2 (enExample)
EP (2) EP1301495A2 (enExample)
JP (2) JP2004502682A (enExample)
CN (2) CN1450997A (enExample)
AU (3) AU2001282163B2 (enExample)
CA (2) CA2414799A1 (enExample)
HU (2) HUP0301625A3 (enExample)
IL (2) IL153767A0 (enExample)
NO (2) NO20026283L (enExample)
NZ (2) NZ523464A (enExample)
PL (2) PL360353A1 (enExample)
RU (2) RU2003103291A (enExample)
WO (2) WO2002002541A2 (enExample)
ZA (2) ZA200300063B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508188A (ja) * 2004-07-27 2008-03-21 アステラス製薬株式会社 Ｖａｐ−１阻害剤活性を有するチアゾール誘導体

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1450997A (zh) 2000-07-05 2003-10-22 拜奥泰治疗公司 含铜的胺氧化酶的抑制剂
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
TWI336696B (en) 2003-01-27 2011-02-01 Astellas Pharma Inc Thiazole derivatives
KR20120045062A (ko) * 2003-03-31 2012-05-08 가부시키가이샤 아루떼꾸 우에노 혈관 과투과 질환의 치료방법
US7499847B2 (en) 2003-05-26 2009-03-03 Biotie Therapies Corporation Crystalline VAP-1 and uses thereof
FI20031927A0 (fi) * 2003-12-31 2003-12-31 Faron Pharmaceuticals Oy Terapeuttisesti vaikuttavia aineita ja niiden käyttö
US8119651B2 (en) 2004-01-30 2012-02-21 Biotie Therapies Corp. Compositions useful especially for treatment or prevention of metabolic syndrome
FI20040136A0 (fi) * 2004-01-30 2004-01-30 Faron Pharmaceuticals Oy Erityisesti diabeetikoille soveltuvia koostumuksia
CA2549029A1 (en) * 2004-01-30 2005-08-11 Faron Pharmaceuticals Oy Compositions for treatment or prevention of metabolic syndrome
FI20040270A0 (fi) * 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset
EP1791835A2 (en) * 2004-09-09 2007-06-06 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
JP4140630B2 (ja) * 2005-11-10 2008-08-27 Ｔｄｋ株式会社 磁気ヘッドアセンブリ及び磁気ヘッドアセンブリの製造方法
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
FI20061156A0 (fi) 2006-12-27 2006-12-27 Elina Kivi Uusia peptidejä
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
US8426587B2 (en) * 2007-11-21 2013-04-23 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
TWI437986B (zh) 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EP2357252A4 (en) 2008-09-03 2012-05-16 Univ Barcelona Autonoma METHOD AND COMPOSITIONS FOR TREATING AND DIAGNOSIS OF A HEMORRHAGIC CONVERSION
RU2400233C1 (ru) 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
EP2479165B1 (en) 2009-09-16 2017-10-25 Astellas Pharma Inc. Glycine compound
RU2010145439A (ru) 2010-11-08 2012-05-20 Виктор Вениаминович Тец (RU) Средство для лечения поражений печени, вызванных воздействием химических или биологических агентов
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
KR101879011B1 (ko) * 2011-03-15 2018-07-16 아스테라스 세이야쿠 가부시키가이샤 구아니딘 화합물
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
HUE042625T2 (hu) 2014-04-15 2019-07-29 Pecsi Tudomanyegyetem Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
RU2595868C1 (ru) 2015-03-27 2016-08-27 Виктор Вениаминович Тец Лекарственное средство с гепатопротекторной активностью
JP2018076236A (ja) 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
US20180360808A1 (en) 2015-12-07 2018-12-20 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3377345A (en) * 1966-09-23 1968-04-09 Dow Chemical Co Substituted 3, 4, 5, 6-tetrahydro-2h-1, 3, 4-oxadiazin-2-one compounds and method ofpreparation thereof
US3486916A (en) 1966-12-22 1969-12-30 William A Cordon Cement mixes and the production of articles therefrom
SE320311B (enExample) 1968-07-15 1970-02-02 Mo Och Domsjoe Ab
WO1993023023A1 (en) * 1992-05-15 1993-11-25 University Of Saskatchewan Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis
US5413634A (en) 1993-08-06 1995-05-09 Arco Chemical Technology, L.P. Cement composition
CA2117585C (en) 1993-09-14 2001-06-05 Edward T. Shawl Cement composition
WO1996006058A1 (en) 1994-08-25 1996-02-29 W.R. Grace & Co.-Conn. Shrinkage reduction cement composition
US5618344A (en) 1995-03-06 1997-04-08 W. R. Grace & Co.-Conn. Cement composition
US5556460A (en) 1995-09-18 1996-09-17 W.R. Grace & Co.-Conn. Drying shrinkage cement admixture
US5603760A (en) 1995-09-18 1997-02-18 W. R. Grace & Co.-Conn. Cement admixture capable of inhibiting drying shrinkage and method of using same
CN1450997A (zh) 2000-07-05 2003-10-22 拜奥泰治疗公司 含铜的胺氧化酶的抑制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508188A (ja) * 2004-07-27 2008-03-21 アステラス製薬株式会社 Ｖａｐ−１阻害剤活性を有するチアゾール誘導体

Also Published As

Publication number Publication date
NZ523464A (en) 2003-10-31
CA2414807A1 (en) 2002-01-10
NO20026282D0 (no) 2002-12-30
US20040106654A1 (en) 2004-06-03
HUP0301336A3 (en) 2005-04-28
ZA200300063B (en) 2003-07-22
ZA200300064B (en) 2003-07-22
IL153766A0 (en) 2003-07-06
JP2004501962A (ja) 2004-01-22
EP1301495A2 (en) 2003-04-16
US20020173521A1 (en) 2002-11-21
AU8216301A (en) 2002-01-14
NO20026283L (no) 2003-02-28
CN1450998A (zh) 2003-10-22
CA2414799A1 (en) 2002-01-10
AU2001282162A1 (en) 2002-01-14
AU2001282163B2 (en) 2004-12-09
PL360374A1 (en) 2004-09-06
NO20026282L (no) 2003-03-03
WO2002002541A3 (en) 2002-04-18
CN1450997A (zh) 2003-10-22
EP1313718A2 (en) 2003-05-28
WO2002002090A2 (en) 2002-01-10
RU2003103286A (ru) 2004-08-20
RU2003103291A (ru) 2005-01-27
IL153767A0 (en) 2003-07-06
NZ523463A (en) 2004-06-25
HUP0301625A3 (en) 2005-04-28
WO2002002090A3 (en) 2002-05-16
US6624202B2 (en) 2003-09-23
HUP0301336A2 (hu) 2003-08-28
NO20026283D0 (no) 2002-12-30
WO2002002541A2 (en) 2002-01-10
HUP0301625A2 (hu) 2003-11-28
PL360353A1 (en) 2004-09-06

Similar Documents

Publication Publication Date Title
HUP0301625A2 (hu) Réztartalmú amin-oxidáz inhibitor hatású 1,3,4-oxadiazin-vegyületek, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
EP1414426B1 (en) Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
AU2002243323B2 (en) Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
AU2001282163A1 (en) Inhibitors of copper-containing amine oxidases
JP4366186B2 (ja) アデノシンＡ２ａ受容体のリガンドとして有用なトリアゾリル−イミダゾピリジンおよびトリアゾリルプリンの誘導体およびその薬物としての使用
IE52170B1 (en) (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine,antidepressant
EP1096926B1 (en) Methods and compounds for treating depression
US4598084A (en) Optically active derivatives of N-arylated oxazolidine-2-one, the process for preparing same and their application in therapeutics
JPH05507072A (ja) Ｅｇｆレセプタチロシンキナーゼを阻害する複素環式エテンジイル化合物
JP2007524620A (ja) 二重機能性化合物及びその使用
WO2005080319A1 (en) Hydrazino alcohol derivatives useful as inhibitors of copper-containing amine oxidases
CN111808056B (zh) 多巴胺d2受体选择性激动剂及其在疾病治疗中的应用
US3365464A (en) 7-alkyl-3-(2-aminobutyl) indoles
US6500820B1 (en) Pharmaceutical composition for neurotrophic action
CN117440811A (zh) 用于治疗与核糖体障碍相关的贫血的组合物和方法
AU2002354626A1 (en) Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
MX2008002807A (en) Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-but oxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
HK1058794A (en) Inhibitors of copper-containing amine oxidases

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20051117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051117